Weisheng Pharmaceutical-B (02561) core products were approved to start commercialization and achieved revenue of 35.542 million yuan in the first half of the year

According to the Zhitong Finance App, Weisheng Pharmaceutical-B (02561) announced its 2026 interim results, achieving revenue of 34.542 million yuan and gross profit of 18.062 million yuan. The cost of research and development was 37.374 million yuan, a year-on-year decrease of 19.83%. The loss for the period was approximately RMB 104 million, a year-on-year decrease of 11.79%.

Injectable lonapegsomatropin (lonapegsomatropin) (Chinese product name: Weizhengo®; English product name: SKYTROFA®) was approved by the State Drug Administration on January 26, 2026, marking that the company has officially become a commercialized company. During the reporting period, the company fully launched the commercialization of lonapegsomatropin (lonapegsomatropin) and made substantial progress in product supply, channel construction, commercial coverage, doctor interaction and patient support.

According to the announcement, the revenue was mainly due to the initial commercialization of the core product lonapegsomatropin (lonapegsomatropin) for injection (product name in China: Weizhengo® and English product name: SKYTROFA®).

The reduction in research and development costs is mainly due to the completion of imported BLA registration of the core product lonapegsomatropin (lonapegsomatropin) and the completion of major clinical activities of palopegteriparatide (palopegteriparatide) and navepegritide (navepegritide).